Drugs / CMAB017
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06933069 | Jun 2025 → May 2026 overdue | cancer | Taizhou Mabtech Pharmaceutical Co.,Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMAB017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06933069 ↗ |
| Route | Intravenous | “Administration was by intravenous infusion” NCT06933069 ↗ |